Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): A randomized multicenter study

Authors
Publication date
1 January 2021
Publisher
Digital Commons@Becker

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Digital Commons@Becker

    redirect
    oaioai:digitalcommons.wustl.edu:o...
    Last time updated on 01/12/2021